West Family Investments, Inc. Cidara Therapeutics, Inc. Transaction History

West Family Investments, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Feb 15, 2022	BUY	$1.48 - $2.35 $545,986 - $866,938	368,910 New	368,910 $826,000
Q3 2021 Oct 25, 2021	SELL	$1.48 - $2.35 $545,986 - $866,938	-368,910 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$2.85 - $4.1 $196,393 - $282,531	68,910 Added 22.97%	368,910 $1.05 Million
Q2 2020 Aug 12, 2020	SELL	$2.39 - $4.0 $164,694 - $275,640	-68,910 Reduced 18.68%	300,000 $1.11 Million
Q1 2020 May 08, 2020	BUY	$1.74 - $4.26 $119,903 - $293,556	68,910 Added 22.97%	368,910 $915,000
Q2 2019 Aug 08, 2019	BUY	$1.49 - $2.94 $131,310 - $259,096	88,128 Added 41.59%	300,000 $504,000
Q1 2019 May 13, 2019	BUY	$2.35 - $3.27 $27,899 - $38,821	11,872 Added 5.94%	211,872 $0
Q3 2018 Nov 13, 2018	BUY	$3.7 - $5.25 $170,666 - $242,161	46,126 Added 29.98%	200,000 $880,000
Q2 2018 Aug 09, 2018	BUY	$3.75 - $6.05 $202,027 - $325,937	53,874 Added 53.87%	153,874 $800,000
Q3 2017 Nov 13, 2017	BUY	$5.75 - $8.1 $575,000 - $810,000	100,000	100,000 $810,000

Ticker CDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,075,696
Market Cap $1.43B
Description
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifu...

Get notified when there are updates to the investment portfolio of West Family Investments, Inc., based on Form 13F filings with the SEC.

Stay updated on West Family Investments, Inc. with notifications on news.